An analysis of the attrition of drug candidates from four major pharmaceutical companies
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Waring et al., 2015
In the citing paper
“When using a polylactic acid–polyethylene glycol copolymer, the embedding rate reached 90%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“Su et al. found that, when polylactic acid was used as the membrane material, the embedding rate of hemoglobin was very low, only 7.9%.”
From Synthesis and Biological Application of Polylactic Acid (2020) · cites this paper as [87]
In the citing paper
“The attrition rates in Phase II and Phase III development stages have been reported to be as high as 80% [75,344].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [75]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Self-citationLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Self-citation
Cited by
Items 201–300 of 1,001
Pointon, A., Pilling, J., Dorval, T., Wang, Y., Archer, C., & Pollard, C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw227 · Cited by 66
Sayed, N., Khurana, A., & Godugu, C. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101201 · Cited by 75
Sepp, K., Lee, M. W., Bluntzer, M. T. J., Helgason, G. V., Hulme, A. N., & Brunton, V. G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01546 · Cited by 75
Three dimensional bioprinting technology: Applications in pharmaceutical and biomedical area
Koçak, E., Yıldız, A., & Acartürk, F. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111396 · Cited by 75
In Vitro Immune Organs-on-Chip for Drug Development: A Review
Shanti, A., Teo, J., & Stefanini, C. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040278 · Cited by 65
The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception
Gómara-Lomero, M., & Ramón‐García, S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.001 · Cited by 73
Drug Target Identification in Tissues by Thermal Proteome Profiling
Mateus, A., Kurzawa, N., Perrin, J., Bergamini, G., & Savitski, M. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-013205 · Cited by 73
Kimber, T. B., Gagnebin, M., & Volkamer, A. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100014 · Cited by 73
Drug like potential of Daidzein using SwissADME prediction: In silico Approaches
Sardar, H. (2023) · Phytonutrients · doi:10.62368/pn.vi.18 · Cited by 73
toxCSM: comprehensive prediction of small molecule toxicity profiles
de Sá, A. G. C., Long, Y., Portelli, S., Pires, D. E. V., & Ascher, D. B. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac337 · Cited by 72
From understanding diseases to drug design: can artificial intelligence bridge the gap?
Pushkaran, A. C., & Arabi, A. A. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10714-5 · Cited by 72
Drug repurposing: Clinical practices and regulatory pathways
Saranraj, K., & Kiran, P. U. (2024) · Perspectives in Clinical Research · doi:10.4103/picr.picr_70_24 · Cited by 72
Antibiotics re-booted—time to kick back against drug resistance
Blaskovich, M. A. T., & Cooper, M. A. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00096-1 · Cited by 72
McKeithan, W. L., Savchenko, A., Yu, M. S., Cerignoli, F., Bruyneel, A. A. N., Price, J. H., Colas, A. R., Miller, E. W., Cashman, J. R., & Mercola, M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00766 · Cited by 71
Key indicators of phase transition for clinical trials through machine learning
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S., & Albright, T. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.014 · Cited by 58
In Silico ADME Profiling of Salubrinal and Its Analogues
Zadorozhnii, P. V., Kiselev, V. V., & Kharchenko, A. V. (2022) · Future Pharmacology · doi:10.3390/futurepharmacol2020013 · Cited by 71
Cao, H., Peng, J., Zhou, Z., Yang, Z., Wang, L., Sun, Y., Wang, Y., & Liang, Y. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c04400 · Cited by 71
The emerging role of in vitro electrophysiological methods in CNS safety pharmacology
Accardi, M. V., Pugsley, M. K., Forster, R. P., Troncy, É., Huang, H., & Authier, S. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.008 · Cited by 71
Pharmacokinetics of lipid-drug conjugates loaded into liposomes
Signorell, R. D., Luciani, P., Brambilla, D., & Leroux, J. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.04.003 · Cited by 71
Genetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 69
Revealing cytotoxic substructures in molecules using deep learning
Webel, H. E., Kimber, T. B., Radetzki, S., Neuenschwander, M., Nazaré, M., & Volkamer, A. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00310-4 · Cited by 66
Goldring, C., Antoine, D. J., Bonner, F., Crozier, J., Denning, C., Fontana, R. J., Hanley, N. A., Hay, D. C., Ingelman‐Sundberg, M., Juhila, S., et al. (2017) · Hepatology · doi:10.1002/hep.28886 · Cited by 58
Stoddart, L. A., Vernall, A. J., Bouzo-Lorenzo, M., Bosma, R., Kooistra, A. J., de Graaf, C., Vischer, H. F., Leurs, R., Briddon, S. J., Kellam, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19714-2 · Cited by 70
Computer-Aided Drug Design: An Overview
Talevi, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7756-7_1 · Cited by 70
Schittny, A., Philipp-Bauer, S., Detampel, P., Huwyler, J., & Puchkov, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.031 · Cited by 70
Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements
Stergiopoulos, C., Tsopelas, F. N., & Valko, K. L. (2021) · ADMET & DMPK · doi:10.5599/admet.995 · Cited by 69
Kok, L. Y., Bannigan, P., Sanaee, F., Evans, J. C., Dunne, M., Regenold, M., Ahmed, L., Dubins, D. N., & Allen, C. J. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106058 · Cited by 69
Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects
Talevi, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3441-7_1 · Cited by 69
Webster, C. I., Hatcher, J., Burrell, M., Thom, G., Thornton, P., Gurrell, I., & Chessell, I. (2017) · Pain · doi:10.1097/j.pain.0000000000000810 · Cited by 63
Van Vleet, T. R., Liguori, M. J., Lynch, III, Rao, M., & Warder, S. (2019) · SLAS Discovery · doi:10.1177/2472555218799713 · Cited by 59
Tagle, D. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.007 · Cited by 68
Yukawa, T., & Naven, R. T. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00536 · Cited by 68
Validating ADME QSAR Models Using Marketed Drugs
Siramshetty, V. B., Williams, J., Nguyễn, Ð.-T., Neyra, J., Southall, N. T., Mathé, E. A., Xu, X., & Shah, P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017520 · Cited by 67
Youhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
Few-Shot Learning for Low-Data Drug Discovery
Vella, D., & Ebejer, J.-P. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00779 · Cited by 67
Curreli, F., Kwon, Y. D., Belov, D. S., Ramesh, R. R., Kurkin, A. V., Altieri, A., Kwong, P. D., & Debnath, A. K. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00179 · Cited by 67
Biomechanical regulation of drug sensitivity in an engineered model of human tumor
Marturano-Kruik, A., Villasante, A., Yaeger, K. A., Ambati, S. R., Chramiec, A. G., Raimondi, M. T., & Vunjak‐Novakovic, G. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.020 · Cited by 67
Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification
Lim, S. H., Sun, Y., Madanagopal, T. T., Rosa, V., & Kang, L. (2018) · Scientific Reports · doi:10.1038/s41598-017-18454-z · Cited by 67
Weston, M., Kaserer, T., Wu, A. J., Mouravlev, A., Carpenter, J. C., Snowball, A., Knauß, S., von Schimmelmann, M. J., During, M. J., Lignani, G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw1567 · Cited by 67
Targeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Advancing drug discovery with deep attention neural networks
Lavecchia, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104067 · Cited by 65
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport
Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.003 · Cited by 64
Practical application of ligand efficiency metrics in lead optimisation
Scott, J. S., & Waring, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.004 · Cited by 54
Self-citationDiscovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 63
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2022) · Cells Tissues Organs · doi:10.1159/000517422 · Cited by 48
Tissue-specific genetic features inform prediction of drug side effects in clinical trials
Duffy, Á., Verbanck, M., Dobbyn, A. L., Won, H., Rein, J. L., Forrest, I. S., Nadkarni, G. N., Rocheleau, G., & Do, R. (2020) · Science Advances · doi:10.1126/sciadv.abb6242 · Cited by 62
Murad, N., Pasikanti, K. K., Madej, B. D., Minnich, A., McComas, J., Crouch, S., Polli, J. W., & Weber, A. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000202 · Cited by 62
Banks, W. A., & Greig, N. H. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0436 · Cited by 51
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61
“Accurate prediction of pharmacokinetic and toxicological properties remains one of the most critical applications of AI in small-molecule drug discovery, as poor ADMET properties account for a significant proportion of late-stage failures [87].”
Vendramin, R., Katopodi, V., Cinque, S., Konnova, A., Knezevic, Z., Adnane, S., Verheyden, Y., Karras, P., Demesmaeker, E., Bosisio, F. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210571 · Cited by 61
Mokaya, M., Imrie, F., van Hoorn, W. P., Kalisz, A., Bradley, A. R., & Deane, C. M. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00636-2 · Cited by 61
Drug Repurposing: A Leading Strategy for New Threats and Targets
Mishra, A. S., Vasanthan, M., & Malliappan, S. P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00361 · Cited by 61
Deep Transferable Compound Representation across Domains and Tasks for Low Data Drug Discovery
Abbasi, K., Poso, A., Ghasemi, J. B., Amanlou, M., & Masoudi‐Nejad, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00626 · Cited by 61
Near‐Infrared Chemiluminescence Imaging of Chemotherapy‐Induced Peripheral Neuropathy
Liu, J., Huang, J., Wei, X., Cheng, P., & Pu, K. (2023) · Advanced Materials · doi:10.1002/adma.202310605 · Cited by 60
hERG quality control and the long QT syndrome
Foo, B., Williamson, B., Young, J. C., Lukács, G. L., & Shrier, A. (2015) · The Journal of Physiology · doi:10.1113/jp270531 · Cited by 60
Hop, P., Allgood, B., & Yu, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01144 · Cited by 60
Context-enriched molecule representations improve few-shot drug discoveryPreprint
Schimunek, J., Seidl, P., Friedrich, L., Kühn, D., Rippmann, F., Hochreiter, S., & Klambauer, G. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2305.09481 · Cited by 60
Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration
Walker, A. L., Imam, S. Z., & Roberts, R. A. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370218801309 · Cited by 59
Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade
Lill, J. R., Mathews, W. R., Rose, C. M., & Schirle, M. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1962300 · Cited by 59
Shaughnessey, E. M., Kann, S. H., Azizgolshani, H., Black, L. D., Charest, J. L., & Vedula, E. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-16590-9 · Cited by 59
Mahapatra, I., Clark, J. R. A., Dobson, P. J., Owen, R., Lynch, I., & Lead, J. R. (2018) · Environmental Science Nano · doi:10.1039/c8en00053k · Cited by 58
Self-citationAleo, M. D., Shah, F., Allen, S. W., Barton, H. A., Costales, C., Lazzaro, S., Leung, L. Y., Nilson, A. L., Obach, R. S., Rodrigues, A. D., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00262 · Cited by 58
Agarwal, S., Sasane, S., Shah, H. A., Pethani, J. P., Deshmukh, P. H., Vyas, V., Iyer, P. S., Bhavsar, H., Viswanathan, K., Bandyopadhyay, D., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00433 · Cited by 58
Serrano, D. R., Persoons, T., D'Arcy, D. M., Galiana, C., Dea‐Ayuela, M. A., & Healy, A. M. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.030 · Cited by 57
Bowman, C. M., & Benet, L. Z. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071514 · Cited by 57
Mochel, J. P., Jergens, A. E., Kingsbury, D. D., Kim, H. J., Martín, M. G., & Allenspach, K. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0178-1 · Cited by 57
Bouzo-Lorenzo, M., Stoddart, L. A., Xia, L., IJzerman, A. P., Heitman, L. H., Briddon, S. J., & Hill, S. J. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09650-9 · Cited by 57
Appelt‐Menzel, A., Oerter, S., Mathew, S., Haferkamp, U., Hartmann, C., Jung, M., Neuhaus, W., & Pleß, O. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.122 · Cited by 57
Sharma, A., Arora, K., Mohapatra, H., Sindhu, R. K., Bulzan, M., Cavalu, S. D., Paneshar, G., Elansary, H. O., El-Sabrout, A. M., Mahmoud, E. A., et al. (2022) · Molecules · doi:10.3390/molecules27092969 · Cited by 56
A History of Regulatory Animal Testing: What Can We Learn?
Swaters, D., van Veen, A., van Meurs, W. P., Turner, J. E., & Ritskes-Hoitinga, M. J. (2022) · Alternatives to Laboratory Animals · doi:10.1177/02611929221118001 · Cited by 56
Hagenbuch, B., Stieger, B., & Locher, K. P. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100023 · Cited by 56
Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress
Loughran, H. M., Han, Z., Wrobel, J. E., Decker, S. E., Ruthel, G. T., Freedman, B. D., Harty, R. N., & Reitz, A. B. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.053 · Cited by 56
Secker, P. F., Schlichenmaier, N., Beilmann, M., Deschl, U., & Dietrich, D. R. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02469-8 · Cited by 56
Targeting pathogen metabolism without collateral damage to the host
Haanstra, J. R., Gerding, A., Dolga, A. M., Sorgdrager, F. J. H., Buist‐Homan, M., du Toit, F., Faber, K. N., Holzhütter, H., Szöőr, B., Matthews, K. R., et al. (2017) · Scientific Reports · doi:10.1038/srep40406 · Cited by 55
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease
Więckowska, A., Wichur, T., Godyń, J., Bucki, A., Marcinkowska, M., Siwek, A., Więckowski, K., Zaręba, P., Knez, D., Głuch‐Lutwin, M., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00024 · Cited by 55
BUSCA VIRTUAL DE COMPOSTOS BIOATIVOS: CONCEITOS E APLICAÇÕES
Piccirillo, E., & do Amaral, A. T. (2018) · Química Nova · doi:10.21577/0100-4042.20170210 · Cited by 54
Model‐Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative
Schneider, B., Balbas‐Martinez, V., Jergens, A. E., Trocóniz, I. F., Allenspach, K., & Mochel, J. P. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12262 · Cited by 54
Lead-like Drugs: A Perspective
Raymer, B. K., & Bhattacharya, S. K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00407 · Cited by 54
Entering the era of computationally driven drug development
Maharao, N. V., Antontsev, V. G., Wright, M. R., & Varshney, J. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1726944 · Cited by 54
Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids
Shahi Thakuri, P., Ham, S. L., Luker, G. D., & Tavana, H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00527 · Cited by 49
Ishii, T., Okai, T., Iwatani-Yoshihara, M., Mochizuki, M., Unno, S., Kuno, M., Yoshikawa, M., Shibata, S., Nakakariya, M., Yogo, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12513-1 · Cited by 48
Sarı, S., Barut, B., Özel, A., Kuruüzüm‐Uz, A., & Şöhretoğlu, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.015 · Cited by 53
Raschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
Mulpuru, V., & Mishra, N. (2021) · ACS Omega · doi:10.1021/acsomega.0c05846 · Cited by 53
Jose, J., Peter, A., Thajudeen, K. Y., Pereira, M. D. L., Athira, V. P., Bhat, S. G., & Michel, H. (2024) · Results in Engineering · doi:10.1016/j.rineng.2024.102060 · Cited by 52
Melle, F., Menon, D., Conniot, J., Ostolaza-Paraiso, J., Argandona, S. M., Oliveira, J., Chen, X., Mendes, B. B., Conde, J., & Fairen‐Jiménez, D. (2025) · Advanced Materials · doi:10.1002/adma.202412757 · Cited by 52
Burley, S. K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100559 · Cited by 52
Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection
Mervin, L., Cao, Q., Barrett, I. P., Firth, M. A., Murray, D., McWilliams, L. J., Haddrick, M., Wigglesworth, M. J., Engkvist, O., & Bender, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00538 · Cited by 52
Peptide-nanoparticle conjugates as a theranostic platform
Kim, S., No, Y. H., Sluyter, R., Konstantinov, K., Kim, Y. H., & Kim, J. H. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215530 · Cited by 51
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics
Gutiérrez, J. M., Casewell, N. R., & Laustsen, A. H. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022024-033544 · Cited by 51
Butler, L. D., Guzzie‐Peck, P., Hartke, J., Bogdanffy, M. S., Will, Y., Diaz, D., Mortimer‐Cassen, E., Derzi, M., Greene, N., & DeGeorge, J. J. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.05.009 · Cited by 51
De novo coiled-coil peptides as scaffolds for disrupting protein–protein interactions
Fletcher, J. M., Horner, K. A., Bartlett, G. J., Rhys, G. G., Wilson, A. J., & Woolfson, D. N. (2018) · Chemical Science · doi:10.1039/c8sc02643b · Cited by 51
Wang, R., Zhang, Z., Liu, B., Xue, J., Liu, F., Tang, T., Liu, W., Feng, F., & Qu, W. (2021) · Biomaterials Science · doi:10.1039/d0bm02221g · Cited by 51
Shi, K., Zhang, J., Zhou, E., Wang, J., & Wang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01518 · Cited by 50
Self-citationArtificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer
Herráiz-Gil, S., Nygren-Jiménez, E., Acosta-Alonso, D. N., León, C., & Guerrero‐Aspizua, S. (2025) · Applied Sciences · doi:10.3390/app15052798 · Cited by 50
Huang, R., Xia, M., Sakamuru, S., Zhao, J., Lynch, C., Zhao, T., Zhu, H., Austin, C. P., & Simeonov, A. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22046-w · Cited by 50
Designer receptor technology for the treatment of epilepsy
Lieb, A., Weston, M., & Kullmann, D. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.059 · Cited by 50
Metadata
- Authors
- Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., & Weir, A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Thomson Reuters (United Kingdom) (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Eli Lilly (United States) (US)
- Corresponding author
- Waring, Michael J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-19
- Volume
- 14
- Issue
- 7
- Pages
- 475-486
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1663154925
- Cited by
- 1,450
- References
- 27
- Citations by year
- 2026: 164 · 2025: 116 · 2024: 148 · 2023: 143 · 2022: 140 · 2021: 131 · 2020: 129 · 2019: 129 · 2018: 129 · 2017: 113 · 2016: 94 · 2015: 11
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- drug attrition, small molecule drug candidates, physicochemical properties, clinical failure, drug safety, compound optimization, oral medication, pharmaceutical industry
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Humans, Statistics as Topic, Drugs, Investigational, Drug Delivery Systems, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.